Kong Yali, Edler Michael C, Hamel Ernest, Britton-Jenkins Asa R, Gillan Omar, Mooberry Susan L, Mu David, Brown Milton L
Department of Biomedical and Translational Sciences, Macon & Joan Brock Virginia Health Sciences at Old Dominion University, Norfolk, VA 23507, United States.
Department of Medical and Molecular Genetics, United States; School of Medicine, Indiana University, Indianapolis, IN 46202, United States.
Bioorg Med Chem. 2024 Dec 15;116:117999. doi: 10.1016/j.bmc.2024.117999. Epub 2024 Nov 10.
The boronic acid group plays an important role in drug discovery. Following our discovery of a boronic acid analog of combretastatin A-4 (CA-4), a series of analogs featuring a boronic acid group on the C phenyl ring of CA-4 was synthesized and evaluated for cytotoxicity, as well as for their ability to inhibit tubulin polymerization, inhibit the binding of [H]colchicine to tubulin and cause depolymerization of cellular microtubules. Modifications on the C ring of CA-4, either eliminating the methoxy group or replacing the C phenyl ring with a pyridine ring, resulted in a reduced potency for inhibiting tubulin polymerization, colchicine binding and cytotoxic activities as compared to CA-4. Replacing the phenol group with a boronic acid group on the C ring of phenstatin led to a slight increase in cytotoxic potency but a decreased potency for inhibition of tubulin assembly and colchicine binding. Moreover, there was a significant decrease in activity by replacing the C phenyl ring with a pyridine ring. Our results indicate the critical importance of the methoxy group on the C ring as well as the importance of the C phenyl ring compared to a pyridine ring, despite the latter providing a nitrogen atom as a hydrogen bond donor/acceptor, which was predicted by molecular modeling to enhance interaction with the target. The decreased activities of our modified CA-4 boronic analogs may be attributed to weakened hydrogen bonding in our docking model based on the crystal structure of colchicine bound to αβ-tubulin. Notably, even though their effectiveness in inhibiting tubulin polymerization and colchicine binding and causing microtubule depolymerization in cells, the majority of these boronic acid analogs exhibited substantial cytotoxicity. This suggests that they may have additional cellular targets that contribute to their cytotoxicity, and this warrants further evaluation of these unique boronic acid compounds as potential anticancer agents.
硼酸基团在药物研发中起着重要作用。在我们发现了康普瑞他汀A-4(CA-4)的硼酸类似物之后,合成了一系列在CA-4的C苯环上带有硼酸基团的类似物,并对其细胞毒性、抑制微管蛋白聚合的能力、抑制[H]秋水仙碱与微管蛋白结合的能力以及导致细胞微管解聚的能力进行了评估。对CA-4的C环进行修饰,要么去除甲氧基,要么用吡啶环取代C苯环,与CA-4相比,导致抑制微管蛋白聚合、秋水仙碱结合和细胞毒性活性的效力降低。在非他汀的C环上用硼酸基团取代酚羟基,导致细胞毒性效力略有增加,但抑制微管蛋白组装和秋水仙碱结合的效力降低。此外,用吡啶环取代C苯环后活性显著降低。我们的结果表明,C环上的甲氧基至关重要,与吡啶环相比,C苯环也很重要,尽管后者提供了一个氮原子作为氢键供体/受体,分子建模预测这会增强与靶点的相互作用。基于秋水仙碱与αβ-微管蛋白结合的晶体结构,我们修饰的CA-4硼酸类似物活性降低可能归因于对接模型中氢键减弱。值得注意的是,尽管这些硼酸类似物在抑制细胞内微管蛋白聚合、秋水仙碱结合和导致微管解聚方面有效,但大多数硼酸类似物都表现出显著的细胞毒性。这表明它们可能有其他导致其细胞毒性的细胞靶点,这值得进一步评估这些独特的硼酸化合物作为潜在抗癌药物的潜力。